Felix Baker
Sits on 16 boards. Overboarded · 16 public boards Last updated September 27, 2026
Time on boards
- Boards served
- 16
- Current seats
- 16
- Board service
- 45 years
- Director since
- 2023
45 years of board service in total across 16 boards, counting each seat separately. Longest: Incyte Corp., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
BeOne Medicines Ltd. June 11, 202683.3%
-
Kymera Therapeutics Inc. June 25, 202587.8%
-
Kiniksa Pharmaceuticals International plc June 3, 202575.3%
-
Kiniksa Pharmaceuticals International plc June 5, 202466.9%
-
Kodiak Sciences Inc June 4, 202467.9%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 2, 2026 | Bicycle Therapeutics plc | Grant or award | +19,000 | — | — |
| Jan 2, 2026 | Bicycle Therapeutics plc | Grant or award | +19,000 | — | — |
| Dec 31, 2025 | Incyte Corp. | Grant or award | +328 | — | — |
| Dec 31, 2025 | Incyte Corp. | Grant or award | +328 | — | — |
| Dec 11, 2025 | Kymera Therapeutics Inc. | Open-market purchase | +167,192 | $86.00 | $14,378,512 |
| Dec 11, 2025 | Kymera Therapeutics Inc. | Open-market purchase | +1,838,621 | $86.00 | $158,121,406 |
| Nov 20, 2025 | Entrada Therapeutics Inc. | Open-market purchase | +1,213 | $9.07 | $11,002 |
| Nov 20, 2025 | Entrada Therapeutics Inc. | Open-market purchase | +13,386 | $9.07 | $121,411 |
| Nov 20, 2025 | Entrada Therapeutics Inc. | Open-market purchase | +1,186 | $9.07 | $10,757 |
| Nov 20, 2025 | Entrada Therapeutics Inc. | Open-market purchase | +13,082 | $9.07 | $118,654 |
| Sep 30, 2025 | Incyte Corp. | Grant or award | +388 | — | — |
| Sep 30, 2025 | Incyte Corp. | Grant or award | +388 | — | — |
| Aug 18, 2025 | Madrigal Pharmaceuticals Inc. | Open-market purchase | +177 | $353.88 | $62,637 |
| Aug 18, 2025 | Madrigal Pharmaceuticals Inc. | Open-market purchase | +1,923 | $353.88 | $680,511 |
| Aug 18, 2025 | Madrigal Pharmaceuticals Inc. | Open-market purchase | +84 | $355.00 | $29,820 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.